Research
Hormonal
The combination of cagrilintide and semaglutide (cagrANDsema) reduced weight by -14.13 kg compared to placebo.
CagrANDsema is an effective treatment option for weight loss in individuals with obesity.
StrongSupportsmedium confidence
Compared to placebo, cagrANDsema reduced weight by - 14.13 kg (95% CI: -16.49, -11.73).
Why this rating
Based on a systematic review and meta-analysis of RCTs.
Source
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li et al. · Biomedicine & Pharmacotherapy · 2024
DOI 10.1016/j.biopha.2024.116150
Meta-analysisCited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →